Enhanced sialylation and in vivo efficacy of recombinant human α-galactosidase through in vitro glycosylation

Youngsoo Sohn, Jung Mi Lee, Heung Rok Park, Sung Chul Jung, Tai Hyun Park, Doo Byoung Oh

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Human α-galactosidase A (GLA) has been used in enzyme replacement therapy for patients with Fabry disease. We expressed recombinant GLA from Chinese hamster ovary cells with very high productivity. When compared to an approved GLA (agalsidase beta), its size and charge were found to be smaller and more neutral. These differences resulted from the lack of terminal sialic acids playing essential roles in the serum half-life and proper tissue targeting. Because a simple sialylation reaction was not enough to increase the sialic acid content, a combined reaction using galactosyltransferase, sialyltransferase, and their sugar substrates at the same time was developed and optimized to reduce the incubation time. The product generated by this reaction had nearly the same size, isoelectric points, and sialic acid content as agalsidase beta. Furthermore, it had better in vivo efficacy to degrade the accumulated globotriaosylceramide in target organs of Fabry mice compared to an unmodified version.

Original languageEnglish
Pages (from-to)157-162
Number of pages6
JournalBMB Reports
Volume46
Issue number3
DOIs
StatePublished - Mar 2013

Keywords

  • Alpha-galactosidase A
  • Enzyme replacement therapy
  • Fabry disease
  • In vitro glycosylation
  • Sialic acid

Fingerprint

Dive into the research topics of 'Enhanced sialylation and in vivo efficacy of recombinant human α-galactosidase through in vitro glycosylation'. Together they form a unique fingerprint.

Cite this